- Home
- ANVS vs TLSA Comparison
ANVS vs TLSA Comparison
Compare ANVS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- TLSA
- Stock Information
- Founded
- ANVS 2008
- TLSA 2013
- Country
- ANVS United States
- TLSA United Kingdom
- Employees
- ANVS N/A
- TLSA 9
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- TLSA Health Care
- Exchange
- ANVS Nasdaq
- TLSA Nasdaq
- Market Cap
- ANVS 44.6M
- TLSA 187.0M
- IPO Year
- ANVS 2020
- TLSA 2000
- Fundamental
- Price
- ANVS $2.36
- TLSA $1.50
- Analyst Decision
- ANVS Strong Buy
- TLSA
- Analyst Count
- ANVS 4
- TLSA 0
- Target Price
- ANVS $18.00
- TLSA N/A
- AVG Volume (30 Days)
- ANVS 485.7K
- TLSA 260.9K
- Earning Date
- ANVS 08-14-2025
- TLSA 07-15-2025
- Dividend Yield
- ANVS N/A
- TLSA N/A
- EPS Growth
- ANVS N/A
- TLSA N/A
- EPS
- ANVS N/A
- TLSA N/A
- Revenue
- ANVS N/A
- TLSA N/A
- Revenue This Year
- ANVS N/A
- TLSA N/A
- Revenue Next Year
- ANVS N/A
- TLSA N/A
- P/E Ratio
- ANVS N/A
- TLSA N/A
- Revenue Growth
- ANVS N/A
- TLSA N/A
- 52 Week Low
- ANVS $1.11
- TLSA $0.63
- 52 Week High
- ANVS $17.88
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- ANVS 48.29
- TLSA 48.99
- Support Level
- ANVS $2.05
- TLSA $1.53
- Resistance Level
- ANVS $3.18
- TLSA $1.81
- Average True Range (ATR)
- ANVS 0.26
- TLSA 0.11
- MACD
- ANVS -0.08
- TLSA -0.01
- Stochastic Oscillator
- ANVS 27.43
- TLSA 11.76
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.